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Abstract: Coordination compounds of Co(II), Ni(II), Cu(II), Zn(II), and Cd(II) with 1,3,4-thiadiazole-2,5-
disulfonamide as ligand were synthesized and characterized by IR andUV spectroscopy, conductimetry and
thermogravimetry. The parent ligand is a very weak carbonic anhydrase (CA) inhibitor, although it
constituted the lead for developing important classes of diuretics. The complex derivatives behave as much
stronger CA inhibitors, with IC0 values around 10
"sM against isozyme CA II, and 10" M against isozyme
CAI.
Introduction
Sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) are
widely used pharmacological agents in the treatment of a variety of disorders.
1-4 They include derivatives
such as acetazolamide 1, methazolamide 2, as well as the recently developed thienothiopyran sulfonamides
3 introduced in clinical medicine as successful topical antiglaucoma drugs.
2,3
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It was recently reported by us
4-6 that the metal complexes of sulfonamides 1-3 behave as
very strong CA inhibitors, and their mechanism of action has also been explained as being due to a dual
inhibition, by means of sulfonamide anions and metal ions, formed by dissociation of the complexes in
dilute solutions during the enzymatic assay. The sulfonamide anions bind thereafter to the catalytically
vital Zn(II) ion within the CA active site, whereas cations probably bind in the neighborhood of active site
residue His-64 (which acts as a proton shuttle during the catalytic turnover s), disturbing in this way the
whole catalytic cycle.
4"7
1,3,4-Thiadiazole-2,5-disulfonamide 4, a compound reported in the classical study of CA
inhibitors ofRoblin and Clapp,
9 was considered to be a very potent inhibitor, and it constituted the lead for
developing important classes of pharmacological agents such as the thiazide saluretics and the high ceiling
diuretics.
3,10 Recently we reinvestigated
11 this compound and showed that it possesses unexpectedly weak
CA II inhibitory properties, but we were unable to explain why the previous researchers obtained erroneous
data.
9 What is more important is the fact that although a weak inhibitor, 4 was a good lead molecule, since
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it constituted the starting point for obtaining such widely used drugs as chlorothiazide or furosemide.
3,11
As we are also interested in exploring the coordination chemistry of sulfonamide CA
inhibitors, in addition to their pharmacological applications,
1,4,,11 a study is reported here on the
preparation and characterization of metal complexes containing 4 and divalent metal ions such as Co(II),
Ni(II), Cu(II), Zn(II), and Cd(II). In fact 4 is the first disulfonamide for which such a study was done. Here
we report the data on these new derivatives, as well as their inhibition properties against two isozymes, CA
I and CA II. Mention should be made that CA I inhibition data for the parent ligand, 1,3,4-thiadiazole-2,5-
disulfonamide are published here for the first time.
Materials and Methods
Melting points were recorded on a heating plate microscope and are not corrected. FTIR
spectra were obtained on thin films of pure compound, with a Perkin Elmer 1600 instrument, in the range
200 4000 cm"1. Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference,
with a Perkin Elmer Lambda 17 apparatus. Conductimetric measurements were done in DMF solutions, at
25C (concentrations of 1 mM of complex) with a Fisher conductimeter. 1n- and 13C-NMR data were
obtained in DMSO-d as solvent with a Varian Gemmini 300 spectrometer. Chemical shifts are expressed
as values relative to tetramethylsilane as internal standard. Elemental analyses were done by combustion
for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were + 0.4%
of the theoretical values. Thermogravimetric measurements were done in air, at a heating rate of 10C/min.,
with a Perkin Elmer 3600 thermobalance.
Sulfonamide 4 used in the syntheses was prepared as described earlier by us.
11 Metal salts,
organic reagents used for preparing the ligand 4 and solvents were from Aldrich and were used without
additional purification. Bovine CA II and human CA I was from Sigma Chemical Co. Inhibitors were
assayed by March’s micromethod 12, in the conditions of the E-I (enzyme-inhibitor) technique, at 0C in
veronal buffer. IC0 values represent the molarity of inhibitor producing a 50% decrease of CA specific
activity for the CO2 hydration reaction.
Synthesis of coordination compounds 5-9
An amount of 10 mMoles of sulfonamide 4 was converted into the disodium salt, by
dissolving in a solution obtained from 20 mMoles ofNaOH and 15 mL water. The disodium salt obtained in
this way was treated then with a solution of metal salt (MC12 .xH20, where M Co(II), Ni(II), Zn(II),
Cd(II) and Cu(II) ), in ethanol, working at molar ratios sulfonamide M(II) of 1:1. The complexes 5-9
precipitated immediately, were filtered and air dried. Yields were in the range of 50-60%.
Synthesis of coordination compounds 10-14
10 mMoles sulfonamide 4 were suspended in 25 mL of concentrated ammonia solution
and stirred energetically till complete dissolution, then 10 mMoles ofMC12 (as above) dissolved in a small
amount of water were added dropwise. The precipitated complexes were filtered and air dried. Yields were
higher than for the previous complexes (70-75%).
Results and Discussion
Two approaches were used for the preparation of complexes containing 1,3,4-thiadiazole-
2,5-disulfonamide as ligand, both of which were widely employed before by us
6b,13 and by Borras’
6o,14
group for preparing acetazolamide 1 and methazolamide 2 complexes, some of which were subsequently
characterized extensively by spectroscopic and X-ray crystallographic methods. According to our method
6a the coordination compounds of sulfonamides were prepared starting from the sodium salt of the ligand, in
aqueous milieu, whereas according to Borras’ group they were obtained in the presence of ammonia (or
other amines, such as pyridine, ethylenediamine, imidazole, etc), in alcohol as solvent.
14 In such cases, the
amines are also coordinated to the metal ions, in addition to the sulfonamide ligands. In the present study,
we prepared and characterized both types of derivatives, working with the sodium salt of 4, but also with the
ligand in the presence of ammonia, in both cases in a 1:1 molar ratio ligand:metal salt.
The new derivatives prepared in this study, containing 4 and the following metal ions,
Co(II), Ni(II),Cu(II), Zn(II), and Cd(II), oftype 5-14, are shown in Table I, together with their elemental
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analysis data (within + 0.4% of the theoretical values).
Table I: Complexes 5-14 prepared and their elemental analysis data (S stands for the doubly deprotonated
species of sulfonamide 4).
No. Compound Color Analysis (calc./found)
oMa ocb %H
b %N
b
5 [Co;(OH2)2]a black-violet 17.5/17..2
6 [NiS(OH2)2]n deep green 17.4/17.1
7 [CuS(OH2)2]n olive 18.6/18.4
8 [ZnS] white 21.2/20.9
9 [CdS(OH2)2] white 28.8/28.5
10 [CoS(NH3)2]n black-violet 17.6/17..3
11 [NiS(NH3)2], deep blue 17.5/17.1
12 [CuS(NH3)2] blue 18.7/18.5
13 [ZnS(NH3)2] white 19.1/18.8
14 [CdS(NH3)2]o white 28.9/28.5
7.1/6.9 1.8/1.6 16.6/16.4
7.1/7.1 1.7/1.5 16.6/16.5
7.0/6.8 1.7/1.6 16.4/16.1
7.8/7.5 0.7/0.6 18.2/18.1
6.1/5.9 1.5/1.2 14.3/14.2
7.1/6.9 2.4/2.3 25.0/24.8
7.1/6.8 2.4/2.0 25.1/24.8
7.0/6.7 2.3/2.0 24.7/24.6
7.0/6.8 2.3/2.2 24.6/24.2
6.1/5.7 2.0/2.1 21.6/21.3
aBy gravimetry; bBy combustion
The prepared derivatives were further characterized by spectroscopic, thermogravimetric
and conductimetric measurements. In Table II some of these data are shown, more specifically the
sulfonamido vibrations in the IR spectra of the ligand 4 and complexes 5-14, as well as electronic
absorption bands, thermogravimetric (TG) analysis and conductimetric data of these compounds.
Table II: Spectroscopic, magnetic and conductimetric data for complexes 5-10 as compared to ligands 4.
Comp. IR. Spectra ,cm’l
v(SO2)S v(SO2)as
Electronic Spectra b, TG
v (cm") calc./found
Conductimetry d,
AM (f-I xcmxmol-)
4 1107 1378 34
5 1088 1351 8,300; 17,500; 20,400 11.1/10.7 54
6 1087 1348 9,450; 15,800; 26,300 10.7/10.5 28
7 1087 1350 16,200 10.8/10.5 18
$ 1088 1347 21
9 1085 1357 9.2/9.1 27
10 1086 1361 8,850; 17,800; 20,300 10.2/10.1 f 29
11 1085 1360 9,100; 16,000; 26,300 10.1/9.9 f 36
12 1088 1359 16,200 10.0/9.6 f 31
13 1086 1359 10.2/9.9 f 22
14 1087 1358 8.7/8.5 f 30
a FTIR spectra of thin films of pure compound; b Diffuse reflectance spectra in MgO as reference; c Weight
loss between 110-180C for compounds 5-9, and 70-120C for compounds 10-14;
d Solution 10-3 M, in
DMF, at 25C; Corresponding to 2 H20 for a metal ion; e Corresponding to 2 NH3 for a metal ion.
In the FTIR spectra of 4 the strong SO2 vibrations were evidenced at 1107 (symmetrical)
and 1378 (asymmetrical) cm1, respectively, whereas NH2 stretching vibrations appeared at 3080 cm"1. For
complexes 5-14 little differences were evidenced in the IR spectra, as compared to those of the ligand 4, and
they consisted in: (i) shifting of the two sulfonamide bands, with about 20-30 cm
"1 towards lower
wavenumbers as compared to the corresponding bands of the ligand. This behavior was well documented for
other complexes of heterocyclic sulfonamides, such as 1-3, previously reported,
1,4,6,13,14 and clearly indicates
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that the deprotonated sulfonamido moiety interacts with the metal ions, a fact confirmed by X-ray
crystallographic studies of several Zn(II) and Cu(II) complexes containing acetazolamide 1, methazolamide
2 or other sulfonamides of this type
4o,11,13,14 (ii) the shift of the v(NH2) vibration at 3020-3030 cmq, in the
spectra of the sodium salt of 4 as well as in that of complexes 5-14 (data not shown); (iii) in the spectra of
the ammonia-containing complexes, 10-14, such an additional band appears at 3345-3350 cm"1, due to
coordinated NH3 molecules; (iv) the presence ofbands around 340 and 399 cm
1 in the spectra of complexes
5-14, tentatively assigned as due to M-N andM-O vibrations.
13,14,15
In the diffuse reflectance spectra of the Co(II) complexes 5 and 10, an intense band with
three maxima, around 8,500; 17,500, and 20,300 cm"1, respectively was evidenced, which is characteristic
for this ion in octahedral geometry. 16’17 The two Ni(II) complexes, 6 and 11, present a similar spectrum,
again with three maxima, around 9,100-9,500; 15,800-16,000 and 26,300 cm"1, respectively, which is
typical for Ni(II) in octahedral surrounding.
18 For the two Cu(II) complexes, 7 and 12, a structureless wide
band centered at 16,200 cm
"1 was observed, similarly with that of the acetazolamide complexes of Cu(II)
previously reported by us
4a and by Borras’ group,
14 which contain Cu(II) in octahedral geometry. Probably
derivatives 7 and 12 are octahedral too, as other Cu(II) complexes with this type of ligands, described by
Raper.
19
The 1H- and 13C-NMR spectra of ligand 4 are very simple due to the high symmetry of the
molecule. A broad signal at 7.20 ppm due to the SONH2 protons is seen in the 1H-NMR spectrum, and one
signal at 162.4 ppm in the 13C-NMR spectrum.
11 For the Zn(II) complexes 8 and 13 no signals were
detected around 7 ppm in the proton spectra, whereas in the 13C-NMR spectra the signal was shifted at
169.5 ppm (for 8), and 171.2 ppm (for 13), respectively, possibly due to the neighborhood of the cation.
Although fewNMR data were published for complexes of sulfonamides, a similar behavior was documented
by Casanova for the Zn(II) derivative of sulfathiazole.
20
From the conductimetric data of Table II one can see that all the prepared complexes, as
well as the original ligand, behave as non-electrolytes, in contrast to the disodium salt which is a 2:1
electrolyte (data not shown).
O O O O HNS.,S,.NH
2 2 HISSESISNH
L L LM
H, I, ,I HN N---N
"" "s ’A"s 02 02 02 02
5-7,9:L=OH 8:noLpresent
2
10-14 L = NH
Correlating the above data with the TG analysis (Table II), which proved that two water
and two ammonia molecules per metal ion, respectively, are also coordinated to these (with one exception,
which is the Zn(II) derivatives 8), one can presume that the geometry of central ions in the prepared
complexes is tetrahedral for the Zn(II) derivative 8, and octahedral (with two coordinated water or ammonia
molecules) for all other derivatives. Considering 4 as a tetradentate ligand, by means of the two ionized
sulfonamido nitrogens, and the two endocyclic nitrogens (as for the related bidentate ligand, acetazolamide
1, previously investigated) the polymeric structures shown above are proposed for the synthesized
complexes, which would also explain their very low solubility in the majority of solvents. Practically. in
contrast to other sulfonamide complexes, derivatives 5-14 have a moderate or very low solubility in DMSO
andDMF too.
Complexes 5-14 prepared in this study were tested for their ability to inhibit carbonic
anhydrase ( (human isozyme I and bovine isozyme II were used in these assays). In Table III IC0 values are
presented for these compounds, comparatively with the corresponding data of the ligand 4 as well as the
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standard CA inhibitors, acetazolamide 1 and methazolamide 2.
Table III: CA I and II inhibition data, for CO2 hydration, with compounds 1-14, determined by Maren’s
method, lO
Compound ICo (nM)"
CA I CA II
1 200
b 7
b
2 10 8
4 3.5.10 10
4 d
5 345 30
6 390 45
7 175 24
8 210 28
9 180 17
10 360 42
11 440 41
12 185 27
13 205 22
14 185 19
"Molarity of inhibitor (calculated as for the monomer for complexes) producing a 50% decrease of enzyme
specific activity for the CO2 hydration reaction, at 0C; From refs. 1,3; From ref. 9_1; a From ref. 1.
Two things are very striking regarding data of Table III. First, the very weak inhibitory
properties of disulfonamide 4 towards both CA isozymes investigated (data on CA I were not published
before). Although structurally related to acetazolamide 1 and methazolamide 2, the disulfonamide 4 is 103-
104 times a weaker CA inhibitor towards both these isozymes, as compared to the clinically used derivatives
1 and 2. Thus, as shown earlier on CA II,
11 and confirmed here for the other red cell isozyme CA I, 4 has
inhibitory properties comparable to those ofbenzene-1,3-disulfonamide. The other surprising fact is that, in
contrast to 4, its metal complexes prepared by us, of the type 5-14, are much stronger CA inhibitors, a
characteristic shared with all other complexes of heterocyclic sulfonamides reported in the last period by
this group. 1’5 As shown in the introduction, this is due to the dual mechanism of inhibition of such
compounds. Activity is dependent on the metal ion present in these compounds, with Cu(II), Cd(II) and
Zn(II) derivatives being the most effective, towards both CA isozymes investigated.
In conclusion, this is the first report of metal complexes of a heterocyclic disulfonamide,
which possess very strong CA I and CA II inhibitory properties, although the ligand itself, a historically
important molecule for the development of diuretic agents, is weakly inhibitory. The new compounds
prepared were characterized by standard procedures, and a polymeric structure was proposed for all of them.
Unfortunately, due to their poor solubility in usual solvents, no good crystal for X-ray diffraction
experiments could be obtained.
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